Fairvalue-Calculator Fairvalue-Calculator
EN DE

Bio-Rad Laboratories, Inc (BIO) Fair Value & Analysis

Healthcare · US · Market cap $8.2B

Price$270.32
Fair Value$416.63
Upside+54.1%
Quality95/100
Evidence: High Range $312.48 – $520.79

Analysis

Bio-Rad Laboratories, Inc (BIO) currently trades at $270.32, while our model-based Fair Value estimate is $416.63 — implying the stock looks roughly 54.1% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, in…

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABTT34) -83% Stryker Corporation (S1YK34) -89% Medtronic plc (MDT) -7% Boston Scientific Corporation (B1SX34) -81% Edwards Lifesciences Corporation (EW) -52% Siemens Healthineers AG (SEMHF) +19%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.